Exploring kidney dialysis costs in the United States: a scoping review
CONCLUSIONS: These findings indicate that prevention of or delay in progression to ESRD could have considerable cost savings for Medicare and private payers, particularly in patients with high-risk conditions such as type 2 diabetes. More efficient use of resources is needed, including low-cost medication, to improve clinical outcomes and lower overall costs, especially in high-risk groups. Widening access to PD where it is safe and appropriate may help to reduce dialysis costs.PMID:38605648 | DOI:10.1080/13696998.2024.2342210 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Authors: Fiona Stewart Kristin Kistler Yuxian Du Rakesh R Singh Bonnie B Dean Sheldon X Kong Source Type: research
Addendum
J Med Econ. 2024 Jan-Dec;27(1):605. doi: 10.1080/13696998.2024.2340918. Epub 2024 Apr 12.NO ABSTRACTPMID:38607231 | DOI:10.1080/13696998.2024.2340918 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Source Type: research
Exploring kidney dialysis costs in the United States: a scoping review
CONCLUSIONS: These findings indicate that prevention of or delay in progression to ESRD could have considerable cost savings for Medicare and private payers, particularly in patients with high-risk conditions such as type 2 diabetes. More efficient use of resources is needed, including low-cost medication, to improve clinical outcomes and lower overall costs, especially in high-risk groups. Widening access to PD where it is safe and appropriate may help to reduce dialysis costs.PMID:38605648 | DOI:10.1080/13696998.2024.2342210 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Authors: Fiona Stewart Kristin Kistler Yuxian Du Rakesh R Singh Bonnie B Dean Sheldon X Kong Source Type: research
Addendum
J Med Econ. 2024 Jan-Dec;27(1):605. doi: 10.1080/13696998.2024.2340918. Epub 2024 Apr 12.NO ABSTRACTPMID:38607231 | DOI:10.1080/13696998.2024.2340918 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Source Type: research
Exploring kidney dialysis costs in the United States: a scoping review
CONCLUSIONS: These findings indicate that prevention of or delay in progression to ESRD could have considerable cost savings for Medicare and private payers, particularly in patients with high-risk conditions such as type 2 diabetes. More efficient use of resources is needed, including low-cost medication, to improve clinical outcomes and lower overall costs, especially in high-risk groups. Widening access to PD where it is safe and appropriate may help to reduce dialysis costs.PMID:38605648 | DOI:10.1080/13696998.2024.2342210 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Authors: Fiona Stewart Kristin Kistler Yuxian Du Rakesh R Singh Bonnie B Dean Sheldon X Kong Source Type: research
Addendum
J Med Econ. 2024 Jan-Dec;27(1):605. doi: 10.1080/13696998.2024.2340918. Epub 2024 Apr 12.NO ABSTRACTPMID:38607231 | DOI:10.1080/13696998.2024.2340918 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 12, 2024 Category: Health Management Source Type: research
Costs associated with adverse events during treatment episodes for adult attention-deficit/hyperactivity disorder
Conclusions: This study found that AEs occurring during ADHD treatment episodes are associated with significant healthcare costs. This highlights the potential of treatments with favorable safety profiles to alleviate the burden experienced by patients and the healthcare system.PMID:38602691 | DOI:10.1080/13696998.2024.2342749 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 11, 2024 Category: Health Management Authors: Jeff Schein Martin Cloutier Rebecca Bungay Marjolaine Gauthier-Loiselle Ann Childress Source Type: research
Correction
J Med Econ. 2024 Jan-Dec;27(1):606. doi: 10.1080/13696998.2024.2341210. Epub 2024 Apr 10.NO ABSTRACTPMID:38597236 | DOI:10.1080/13696998.2024.2341210 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 10, 2024 Category: Health Management Source Type: research
Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
CONCLUSION: This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.PMID:38590236 | DOI:10.1080/13696998.2024.2340932 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 9, 2024 Category: Health Management Authors: Karissa Johnston Lauren C Powell Evan Popoff Gil J L'Italien Robert Pawinski Aideen Ahern Sam Large Thang Tran Aaron Jenkins Source Type: research
Economic impact analysis of a minimally invasive temperature-controlled radiofrequency device versus nasal surgery for the treatment of nasal airway obstruction in the United States
Conclusions: In patients with severe/extreme NAO, with NVC as the primary or major contributor, introducing TCRF with ITR as a treatment option demonstrates the potential for significant cost savings over functional rhinoplasty with septoplasty and ITR.PMID:38581156 | DOI:10.1080/13696998.2024.2340385 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 6, 2024 Category: Health Management Authors: Michael Yong Desiree Hollemon Julie Baxter Alex Hirst Sam Bryning Aimee Fox Greg Smith Robert Hughes Giulia Brandolini Scott Wolf Randall Ow Source Type: research
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
CONCLUSIONS: A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions and antimicrobial-resistant infections and would be cost saving in the US.PMID:38577742 | DOI:10.1080/13696998.2024.2339638 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - April 5, 2024 Category: Health Management Authors: Mark H Rozenbaum Liping Huang Alejandro Cane Adriano Arguedas Ruth Chapman Desmond Dillon-Murphy Maria Tort Vincenza Snow Erica Chilson Raymond Farkouh Source Type: research
